vzv vaccines

o'donnell

VZV virus family

herpes simplex, Epstein-Barr (EBV)

VSV latency

life-long infection, virus goes into dormancy

VSV disease states

chicken pox & shingles/herpes zoster

chicken pox clinical presentation

1st exposure to VS

fever @ 1-2days, itchy rash w/ papules & blisters @ 10-21 days

chicken pox complications

encephalitis, pneumonia, sepsis, secondary bacterial infection

shingles/herpes zoster clinical presentation

VSV exits latency w/ itchy/painful rash in bands around areas innervated by infected ganglia

shingles/herpes zoster comlications

post-herpetic neuralgia, encephalitis, vision/hearing loss

immune system recognizing VSV @ start of infection

innate immunity

target of stimulation of innate response in order to fight the virus

Tcells (CMI) & Bcell (antibody production)

2 requirements for resolving infection

CMI & antibodies

purpose of memory Tcells (CD4 & CD8)

prevent VSV reactivation

timing for 1^st dose of Varivax (children)

12-15months due to weaning of mother’s antibodies

timing for 2^nd dose of Varivax (children)

4-6yrs

varivax vaccine type

low dose of live-attenuated Oka strain created in lab, NO latency

plaque forming unit (PFU)

measure of # of viral particles

adult vaccines for VZV

varivax, Shingrix (zoster recombinant)

reasoning for varivax on adult vaccine schedule

adult w/o VZV exposure or virus (zero immune experience)

shingrix vaccine

shingles prevention

age for shingles vaccine

50+

zostavax

live attenuated Oka strain, discontinued

3 drawbacks of zostavax

efficacy decreases w/ age, vaccine effectiveness wanes over time, contraindicated in the immunocompromised